194 related articles for article (PubMed ID: 38129686)
1. Atomistic ensemble of active SHP2 phosphatase.
Anselmi M; Hub JS
Commun Biol; 2023 Dec; 6(1):1289. PubMed ID: 38129686
[TBL] [Abstract][Full Text] [Related]
2. Discriminating between competing models for the allosteric regulation of oncogenic phosphatase SHP2 by characterizing its active state.
Calligari P; Santucci V; Stella L; Bocchinfuso G
Comput Struct Biotechnol J; 2021; 19():6125-6139. PubMed ID: 34900129
[TBL] [Abstract][Full Text] [Related]
3. Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.
Darian E; Guvench O; Yu B; Qu CK; MacKerell AD
Proteins; 2011 May; 79(5):1573-88. PubMed ID: 21365683
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations.
Yu ZH; Zhang RY; Walls CD; Chen L; Zhang S; Wu L; Liu S; Zhang ZY
Biochemistry; 2014 Jul; 53(25):4136-51. PubMed ID: 24935154
[TBL] [Abstract][Full Text] [Related]
5. Experiment-guided molecular simulations define a heterogeneous structural ensemble for the
Marasco M; Kirkpatrick J; Carlomagno T; Hub JS; Anselmi M
Chem Sci; 2023 May; 14(21):5743-5755. PubMed ID: 37265738
[TBL] [Abstract][Full Text] [Related]
6. Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation.
Sha F; Kurosawa K; Glasser E; Ketavarapu G; Albazzaz S; Koide A; Koide S
J Mol Biol; 2023 Apr; 435(8):168010. PubMed ID: 36806475
[TBL] [Abstract][Full Text] [Related]
7. An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphatase.
Anselmi M; Hub JS
Sci Rep; 2020 Oct; 10(1):18530. PubMed ID: 33116231
[TBL] [Abstract][Full Text] [Related]
8. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
[TBL] [Abstract][Full Text] [Related]
9. Structural Determinants of Phosphopeptide Binding to the N-Terminal Src Homology 2 Domain of the SHP2 Phosphatase.
Anselmi M; Calligari P; Hub JS; Tartaglia M; Bocchinfuso G; Stella L
J Chem Inf Model; 2020 Jun; 60(6):3157-3171. PubMed ID: 32395997
[TBL] [Abstract][Full Text] [Related]
10. How a single mutation alters the protein structure: a simulation investigation on protein tyrosine phosphatase SHP2.
Hou Y; Lu X; Xu Z; Qu J; Huang J
RSC Adv; 2023 Jan; 13(7):4263-4274. PubMed ID: 36760301
[TBL] [Abstract][Full Text] [Related]
11. Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition.
LaRochelle JR; Fodor M; Vemulapalli V; Mohseni M; Wang P; Stams T; LaMarche MJ; Chopra R; Acker MG; Blacklow SC
Nat Commun; 2018 Oct; 9(1):4508. PubMed ID: 30375388
[TBL] [Abstract][Full Text] [Related]
12. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK
Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic insights explain the transforming potential of the T507K substitution in the protein-tyrosine phosphatase SHP2.
Zhang RY; Yu ZH; Chen L; Walls CD; Zhang S; Wu L; Zhang ZY
J Biol Chem; 2020 May; 295(18):6187-6201. PubMed ID: 32188694
[TBL] [Abstract][Full Text] [Related]
14. Structural and Functional Consequences of Three Cancer-Associated Mutations of the Oncogenic Phosphatase SHP2.
LaRochelle JR; Fodor M; Xu X; Durzynska I; Fan L; Stams T; Chan HM; LaMarche MJ; Chopra R; Wang P; Fortin PD; Acker MG; Blacklow SC
Biochemistry; 2016 Apr; 55(15):2269-77. PubMed ID: 27030275
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2.
Pádua RAP; Sun Y; Marko I; Pitsawong W; Stiller JB; Otten R; Kern D
Nat Commun; 2018 Oct; 9(1):4507. PubMed ID: 30375376
[TBL] [Abstract][Full Text] [Related]
16. The loops of the N-SH2 binding cleft do not serve as allosteric switch in SHP2 activation.
Anselmi M; Hub JS
Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33888588
[TBL] [Abstract][Full Text] [Related]
17. Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
Müller PJ; Rigbolt KT; Paterok D; Piehler J; Vanselow J; Lasonder E; Andersen JS; Schaper F; Sobota RM
J Proteomics; 2013 Jun; 84():132-47. PubMed ID: 23584145
[TBL] [Abstract][Full Text] [Related]
18. SHP2E76K mutant promotes lung tumorigenesis in transgenic mice.
Schneeberger VE; Luetteke N; Ren Y; Berns H; Chen L; Foroutan P; Martinez GV; Haura EB; Chen J; Coppola D; Wu J
Carcinogenesis; 2014 Aug; 35(8):1717-25. PubMed ID: 24480804
[TBL] [Abstract][Full Text] [Related]
19. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
[TBL] [Abstract][Full Text] [Related]
20. Exploring the effect of E76K mutation on SHP2 cause gain-of-function activity by a molecular dynamics study.
Li WY; Wei HY; Sun YZ; Zhou H; Ma Y; Wang RL
J Cell Biochem; 2018 Dec; 119(12):9941-9956. PubMed ID: 30129165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]